IPSET vs Revised IPSET in Essential Thrombocythemia

1. Why This Comparison Matters

Essential thrombocythemia (ET) risk stratification has moved beyond the old two-tier approach of "age over 60 or prior thrombosis equals high risk." JAK2 V617F status and cardiovascular risk factors add clinically meaningful thrombotic information, but different frameworks use them in different ways.

The result is a common clinic problem: one note says "IPSET intermediate risk," another says "revised IPSET low risk," and a third says "conventional high risk." These statements may all be internally correct, but they are not interchangeable. The goal of this guide is to keep the vocabulary clean.

2. Original vs Revised IPSET vs Conventional ET Risk

3. Original IPSET-Thrombosis

The original International Prognostic Score for Thrombosis in WHO-defined ET was developed to predict arterial and venous thrombosis. It assigns points to four readily available factors:

The IPSET-Thrombosis calculator implements this point-based approach and maps the total score to risk categories. It is particularly useful when a clinic note needs to show exactly why a patient moved from one risk band to another.

4. Revised IPSET-Thrombosis

The revised IPSET-Thrombosis framework simplified the model after reanalyzing the original dataset. It focuses on three adverse variables: prior thrombosis, age >60 years, and JAK2 V617F mutation. The commonly used categories are:

The revised system is easier to remember, but it should not be interpreted as saying cardiovascular risk factors are irrelevant. It simply means they are not part of the revised category assignment. Blood pressure control, diabetes management, smoking cessation, lipid optimization, and cardiovascular review remain part of risk reduction.

5. Practical ET Workflow

1. Confirm the diagnosis: ensure the working diagnosis is ET rather than reactive thrombocytosis, prefibrotic myelofibrosis, polycythemia vera, chronic myeloid leukemia, or another myeloid process.
2. Record thrombotic history carefully: separate arterial, venous, splanchnic, microvascular, and pregnancy-associated events where relevant.
3. Document mutation status: JAK2 V617F is central to both original and revised IPSET. CALR and MPL status may matter for broader ET interpretation even when not directly scored here.
4. Calculate original IPSET when a point score is helpful: open IPSET-Thrombosis for reproducible documentation.
5. Add revised IPSET category in the plan: use the four-category system when discussing treatment intensity, especially in notes that follow contemporary ET management frameworks.
6. Assess bleeding risk before aspirin: consider acquired von Willebrand disease, extreme thrombocytosis, active bleeding, anticoagulation, and gastrointestinal risk.
7. Consider cytoreduction in context: high-risk status often leads to cytoreductive therapy discussion, but age, fertility goals, comorbidities, symptoms, platelet control, and patient preference shape the final plan.

Related hematology tools on OncoToolkit include DIPSS, DIPSS-Plus, IPSS-R, and ELTS. For broader browsing, see the hematology calculator hub.

6. Limitations And Caveats

• Diagnosis matters: IPSET models were developed for WHO-defined ET; applying them to prefibrotic myelofibrosis or reactive thrombocytosis is inappropriate.
• Bleeding risk is separate: thrombosis-risk tools do not replace evaluation for acquired von Willebrand disease, mucosal bleeding, anticoagulant exposure, or platelet-related bleeding risk.
• Therapy decisions are not automatic: aspirin and cytoreduction depend on risk class plus individualized hematology assessment.
• Cardiovascular risk remains actionable: revised IPSET removed CV risk factors from the formal category but not from the care plan.
• Pregnancy and young patients require specialized interpretation: ET management around conception, pregnancy, and postpartum risk should follow specialist guidance rather than calculator outputs alone.

7. Frequently Asked Questions